However, frequent mutations in TP53 in cancer, heterogeneity in the response to altered Δ40p53 expression, limited understanding of the physiological function of ∆40p53, and potential side effects may limit the application of these modulators in clinical settings. This evidence concerns the gene TP53 and cancer.